ScholarLens Back to search
2013•Unpublished venueRequires access

Technology for Hypoglycaemia: CSII and CGM

J.E. Schopman, J. Hans DeVries

Open publisher page 1 citations

Abstract

This chapter describes the technologies with the potential to prevent or limit exposure to hypoglycaemia. These include continuous subcutaneous insulin infusion (CSII) and continuous glucose monitoring (CGM) systems. An overview of the impact of these methods on the occurrence of hypoglycaemic events compared to standard treatment (multiple daily injections (MDI) or home blood glucose monitoring) in patients with type 1 diabetes is given. CSII is effective in reducing the frequency of severe hypoglycaemia. Against expectations, CGM seems unable to prevent hypoglycaemia. The reasons why CGM seems unable to limit exposure to severe, mild and nocturnal hypoglycaemia in patients with type 1 diabetes with and without impaired hypoglycaemia awareness are discussed. We also point to future research that may help reduce hypoglycaemia exposure.

About this research paper

What this paper is about

This chapter describes the technologies with the potential to prevent or limit exposure to hypoglycaemia. These include continuous subcutaneous insulin infusion (CSII) and continuous glucose monitoring (CGM) systems. An overview of the impact of these methods on the occurrence of hypoglycaemic events compared to standard treatment (multiple daily injections (MDI) or home blood glucose monitoring) in patients with type 1 diabetes is given. CSII is effective in reducing the frequency of severe hypoglycaemia. Against expectations, CGM seems unable to prevent hypoglycaemia. The reasons why CGM seems unable to limit exposure to severe, mild and nocturnal hypoglycaemia in patients with type 1 diabetes with and without impaired hypoglycaemia awareness are discussed. We also point to future research that may help reduce hypoglycaemia exposure.

Why it matters

OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

This chapter describes the technologies with the potential to prevent or limit exposure to hypoglycaemia. These include continuous subcutaneous insulin infusion (CSII) and continuous glucose monitoring (CGM) systems. An overview of the impact of these methods on the occurrence of hypoglycaemic events compared to standard treatment (multiple daily injections (MDI) or home blood glucose monitoring) in patients with type 1 diabetes is given. CSII is effective in reducing the frequency of severe hypoglycaemia. Against expectations, CGM seems unable to prevent hypoglycaemia. The reasons why CGM seems unable to limit exposure to severe, mild and nocturnal hypoglycaemia in patients with type 1 diabetes with and without impaired hypoglycaemia awareness are discussed. We also point to future research that may help reduce hypoglycaemia exposure.

Key concepts: Continuous glucose monitoring, Medicine, Type 1 diabetes, Hypoglycemia, Intensive care medicine, Blood Glucose Self-Monitoring, Diabetes mellitus, Pediatrics

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Technology for Hypoglycaemia: CSII and CGM — Research Paper | ScholarLens